Company intelligence / Profile preview
CervoMed
Boston, Massachusetts, United Statescervomed.com ↗
- Ownership
- Public · CRVO
- Employees
- ~50
- Development stage
- Other
01
Overview
CervoMed’s lead asset, neflamapimod, demonstrated clinical proof-of-concept in a phase 2b trial for dementia with Lewy bodies. The company reported positive results from the extension phase of the RewinD-LB study in March 2025 and plans to initiate a pivotal phase 3 trial in DLB by mid–2026 pending FDA feedback and funding[1][5]. Neflamapimod targets synaptic dysfunction via inhibition of p38 MAPKα.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on CervoMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CervoMed.